Additionally, we demonstrated that the anti-tumor effect of NK cells was significantly enhanced by EZH2 inhibitors, and when EZH2 small molecule inhibitors were combined with TIGIT-blocking monoclonal antibodies, the anti-tumor effect of NK cells was higher than that of cells receiving monotherapy, and the expression of NKP30, an NK immune molecule, was increased in primary cells. This evidence concerns the gene NCR3 and neoplasm.